标题
PD-L1 regulation by SDH5 via β-catenin/ZEB1 signaling
作者
关键词
-
出版物
OncoImmunology
Volume -, Issue -, Pages 1655361
出版商
Informa UK Limited
发表日期
2019-09-17
DOI
10.1080/2162402x.2019.1655361
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
- (2018) Li Wang et al. Nature Communications
- Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
- (2018) Alexandra Thomas et al. OncoImmunology
- EMT Transition States during Tumor Progression and Metastasis
- (2018) Ievgenia Pastushenko et al. TRENDS IN CELL BIOLOGY
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200
- (2017) Muhammad Zaeem Noman et al. OncoImmunology
- Downregulation of tumor suppressing STF cDNA 3 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by the Wnt/GSK-3β/β-catenin/Snail signaling pathway
- (2016) Yang-fan Lv et al. CANCER LETTERS
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
- (2015) M. P. Mak et al. CLINICAL CANCER RESEARCH
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Cavity-free plasmonic nanolasing enabled by dispersionless stopped light
- (2014) Tim Pickering et al. Nature Communications
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer--Response
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- Succinate Dehydrogenase 5 (SDH5) Regulates Glycogen Synthase Kinase 3β-β-Catenin-mediated Lung Cancer Metastasis
- (2013) Jun Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lung cancer: potential targets for immunotherapy
- (2013) Eric Tartour et al. Lancet Respiratory Medicine
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
- (2009) B. Li et al. CLINICAL CANCER RESEARCH
- SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma
- (2009) H.-X. Hao et al. SCIENCE
- Targeting AKT Signaling Sensitizes Cancer to Cellular Immunotherapy
- (2008) P. S. Hahnel et al. CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started